254 related articles for article (PubMed ID: 17827141)
1. Hepatotoxicity of oral and intravenous voriconazole in relation to cytochrome P450 polymorphisms.
Levin MD; den Hollander JG; van der Holt B; Rijnders BJ; van Vliet M; Sonneveld P; van Schaik RH
J Antimicrob Chemother; 2007 Nov; 60(5):1104-7. PubMed ID: 17827141
[TBL] [Abstract][Full Text] [Related]
2. Incidence of voriconazole hepatotoxicity during intravenous and oral treatment for invasive fungal infections.
den Hollander JG; van Arkel C; Rijnders BJ; Lugtenburg PJ; de Marie S; Levin MD
J Antimicrob Chemother; 2006 Jun; 57(6):1248-50. PubMed ID: 16556632
[TBL] [Abstract][Full Text] [Related]
3. Intravenous voriconazole after toxic oral administration.
Alffenaar JW; van Assen S; de Monchy JG; Uges DR; Kosterink JG; van der Werf TS
Antimicrob Agents Chemother; 2010 Jun; 54(6):2741-2. PubMed ID: 20385853
[TBL] [Abstract][Full Text] [Related]
4. Lack of hepato- and nephrotoxicity induced by antifungal drug voriconazole in laboratory rats.
Somchit N; Chung JH; Yaacob A; Ahmad Z; Zakaria ZA; Kadir AA
Drug Chem Toxicol; 2012 Jul; 35(3):304-9. PubMed ID: 22288423
[TBL] [Abstract][Full Text] [Related]
5. Monitoring trough voriconazole plasma concentrations in haematological patients: real life multicentre experience.
Racil Z; Winterova J; Kouba M; Zak P; Malaskova L; Buresova L; Toskova M; Lengerova M; Kocmanova I; Weinbergerova B; Timilsina S; Rolencova M; Cetkovsky P; Mayer J
Mycoses; 2012 Nov; 55(6):483-92. PubMed ID: 22429709
[TBL] [Abstract][Full Text] [Related]
6. Comparison of pharmacokinetics and safety of voriconazole intravenous-to-oral switch in immunocompromised adolescents and healthy adults.
Driscoll TA; Frangoul H; Nemecek ER; Murphey DK; Yu LC; Blumer J; Krance RA; Baruch A; Liu P
Antimicrob Agents Chemother; 2011 Dec; 55(12):5780-9. PubMed ID: 21911570
[TBL] [Abstract][Full Text] [Related]
7. Management of voriconazole hepatotoxicity in a lung transplant patient.
Belaiche S; Roustit M; Bedouch P; Quetant S; Saint-Raymond C; Pison C
Transpl Infect Dis; 2011 Jun; 13(3):309-11. PubMed ID: 21176020
[TBL] [Abstract][Full Text] [Related]
8. Comparison of pharmacokinetics and safety of voriconazole intravenous-to-oral switch in immunocompromised children and healthy adults.
Driscoll TA; Yu LC; Frangoul H; Krance RA; Nemecek E; Blumer J; Arrieta A; Graham ML; Bradfield SM; Baruch A; Liu P
Antimicrob Agents Chemother; 2011 Dec; 55(12):5770-9. PubMed ID: 21968355
[TBL] [Abstract][Full Text] [Related]
9. Voriconazole, but not terbinafine, markedly reduces alfentanil clearance and prolongs its half-life.
Saari TI; Laine K; Leino K; Valtonen M; Neuvonen PJ; Olkkola KT
Clin Pharmacol Ther; 2006 Nov; 80(5):502-8. PubMed ID: 17112806
[TBL] [Abstract][Full Text] [Related]
10. Voriconazole: new preparation. Invasive aspergillosis: benefits to be confirmed.
Prescrire Int; 2004 Feb; 13(69):13-6. PubMed ID: 15055210
[TBL] [Abstract][Full Text] [Related]
11. Voriconazole metabolism, toxicity, and the effect of cytochrome P450 2C19 genotype.
Zonios D; Yamazaki H; Murayama N; Natarajan V; Palmore T; Childs R; Skinner J; Bennett JE
J Infect Dis; 2014 Jun; 209(12):1941-8. PubMed ID: 24403552
[TBL] [Abstract][Full Text] [Related]
12. Oral voriconazole for empiric antifungal treatment in patients with uncomplicated febrile neutropenia.
Przepiorka D; Buadi FK; McClune B
Pharmacotherapy; 2008 Jan; 28(1):58-63. PubMed ID: 18154475
[TBL] [Abstract][Full Text] [Related]
13. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes.
Pascual A; Calandra T; Bolay S; Buclin T; Bille J; Marchetti O
Clin Infect Dis; 2008 Jan; 46(2):201-11. PubMed ID: 18171251
[TBL] [Abstract][Full Text] [Related]
14. [Case of pulmonary aspergillosis associated with inappropriate antidiuretic hormone syndrome caused by voriconazole therapy].
Isobe K; Muraoka S; Sugino K; Yamazaki Y; Kikuchi N; Hamanaka N; Takai Y; Shimizu K; Kimura K; Hiroi N; Shibuya K; Homma S
Nihon Kokyuki Gakkai Zasshi; 2007 Jun; 45(6):489-93. PubMed ID: 17644946
[TBL] [Abstract][Full Text] [Related]
15. Correlation between voriconazole trough plasma concentration and hepatotoxicity in patients with different CYP2C19 genotypes.
Matsumoto K; Ikawa K; Abematsu K; Fukunaga N; Nishida K; Fukamizu T; Shimodozono Y; Morikawa N; Takeda Y; Yamada K
Int J Antimicrob Agents; 2009 Jul; 34(1):91-4. PubMed ID: 19261446
[TBL] [Abstract][Full Text] [Related]
16. Administration of voriconazole in patients with renal dysfunction.
Neofytos D; Lombardi LR; Shields RK; Ostrander D; Warren L; Nguyen MH; Thompson CB; Marr KA
Clin Infect Dis; 2012 Apr; 54(7):913-21. PubMed ID: 22267716
[TBL] [Abstract][Full Text] [Related]
17. Voriconazole drug monitoring in the management of invasive fungal infection in immunocompromised children: a prospective study.
Soler-Palacín P; Frick MA; Martín-Nalda A; Lanaspa M; Pou L; Roselló E; de Heredia CD; Figueras C
J Antimicrob Chemother; 2012 Mar; 67(3):700-6. PubMed ID: 22190607
[TBL] [Abstract][Full Text] [Related]
18. Inherited long QT syndrome revealed by antifungals drug-drug interaction.
Eiden C; Peyrière H; Tichit R; Cociglio M; Amedro P; Blayac JP; Margueritte G; Hillaire-Buys D
J Clin Pharm Ther; 2007 Jun; 32(3):321-4. PubMed ID: 17489884
[TBL] [Abstract][Full Text] [Related]
19. Voriconazole hepatotoxicity in severe liver dysfunction.
Solís-Muñoz P; López JC; Bernal W; Willars C; Verma A; Heneghan MA; Wendon J; Auzinger G
J Infect; 2013 Jan; 66(1):80-6. PubMed ID: 23041040
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of hepatotoxicity with off-label oral-treatment doses of voriconazole for invasive fungal infections.
Gorski E; Esterly JS; Postelnick M; Trifilio S; Fotis M; Scheetz MH
Antimicrob Agents Chemother; 2011 Jan; 55(1):184-9. PubMed ID: 20974867
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
